Skip navigation

Two Conferences Under One Roof – One Devoted to Patient Registries, One Devoted to Real World Evidence

January 30-31, 2019
  • Miami, FL

CBI's Patient Registries & Real World Evidence Summit is the opportunity you’ve been waiting for, combining two events to provide you with customized knowledge on how to disrupt the future of Patient Registries and investigate how to use Real World Evidence for drug development, FDA approval and payer reimbursement.

CREATE YOUR OWN CUSTOMIZED LEARNING EXPERIENCE WITH 12 BREAKOUT SESSIONS:

  • A Practical Guide for Launching an Effective Registry
  • Enhance Pricing and Market Access Decisions
  • The Use of Registry Data to Support Quality Improvements and Meet Regulatory Requirements
  • Enriching Drug Development in the Era of Real World Evidence
  • CASE STUDY — Experience of Planning and Conducting an Observational Registry in a Rare Disease
  • The Promise of AI and Machine Learning for Real World Data Applications
  • Develop a Strategy for Comprehensive Evidence Generation
  • Key Considerations for a Sustainable Registry Model
  • Tackle Operational and Organizational Complexities When Implementing Patient Registries
  • Patient Centricity —
    Strategies for Incorporating Patient-Reported Outcomes
  • Real World Evidence and the Current Regulatory Landscape
  • Utilizing Patient-Reported Outcomes to Measure Comparative Effectiveness and Advance Market Access

Patient Registries & Real World Evidence Summit

Two Conferences Under One Roof – One Devoted to Patient Registries, One Devoted to Real World Evidence

CBI's Patient Registries & Real World Evidence Summit is the opportunity you’ve been waiting for, combining two events to provide you with customized knowledge on how to disrupt the future of Patient Registries and investigate how to use Real World Evidence for drug development, FDA approval and payer reimbursement.

CREATE YOUR OWN CUSTOMIZED LEARNING EXPERIENCE WITH 12 BREAKOUT SESSIONS:

  • A Practical Guide for Launching an Effective Registry
  • Enhance Pricing and Market Access Decisions
  • The Use of Registry Data to Support Quality Improvements and Meet Regulatory Requirements
  • Enriching Drug Development in the Era of Real World Evidence
  • CASE STUDY — Experience of Planning and Conducting an Observational Registry in a Rare Disease
  • The Promise of AI and Machine Learning for Real World Data Applications
  • Develop a Strategy for Comprehensive Evidence Generation
  • Key Considerations for a Sustainable Registry Model
  • Tackle Operational and Organizational Complexities When Implementing Patient Registries
  • Patient Centricity —
    Strategies for Incorporating Patient-Reported Outcomes
  • Real World Evidence and the Current Regulatory Landscape
  • Utilizing Patient-Reported Outcomes to Measure Comparative Effectiveness and Advance Market Access